Sarepta Therapeutics, Inc. (SRPT) Financials
SRPT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 3.2 billion | 1.7 billion |
| March 31, 2026 | 3.2 billion | 1.7 billion |
| Dec. 31, 2025 | 3.3 billion | 2.2 billion |
| Sept. 30, 2025 | 3.5 billion | 2.2 billion |
SRPT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -8.2 million | 53.9 million |
| March 31, 2026 | -205.8 million | 29.4 million |
| Dec. 31, 2025 | 125.4 million | 30.0 million |
| Sept. 30, 2025 | -42.8 million | 14.9 million |
SRPT Net Income
No data available :(
SRPT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 788.5 million | 847.6 million | 198.2 million |
| March 31, 2026 | 653.2 million | 838.2 million | 198.5 million |
| Dec. 31, 2025 | 939.7 million | 829.0 million | 210.8 million |
| Sept. 30, 2025 | 851.0 million | 1.0 billion | 215.0 million |
SRPT Shares Outstanding
SRPT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 2.6 million | 91.3 million | 107.6 million | - |
| March 31, 2026 | 3.1 million | 154.0 million | 109.0 million | - |
| Dec. 31, 2025 | 5.8 million | 325.3 million | 128.3 million | - |
| Sept. 30, 2025 | 28.2 million | 218.9 million | 91.9 million | - |
SRPT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 401.3 million | 149.4 million |
| March 31, 2026 | 730.8 million | 119.4 million |
| Dec. 31, 2025 | 442.9 million | 398.7 million |
| Sept. 30, 2025 | 399.4 million | 150.8 million |
SRPT Revenue by Segment
Graph available only for paid members. Upgrade to see it.
SRPT
Price: $17.65
52 week price:
Earnings Per Share: -1.61 USD
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 366531
Ebitda: -43.3 millionMarket Capitalization: 1.8 billion